In Section C, individuals will get ABBV-744 and oral navitoclax. In Section D, members will obtain ABBV-744 and ruxolitinib. Individuals will obtain treatment until condition progression or even the individuals are unable to tolerate the study drugs. Total, our present work highlights the potential utilization of ARV-825 in combination with https://abbv-744-clinical-trial-p13578.dgbloggers.com/32359755/abbv-744-in-clinical-trials-for-non-small-cell-lung-cancer-nsclc-options